niclosamide
IND- Indications
- Triple-negative breast cancer, Ovarian cancer, Uterine cancer, Esophageal cancer, Prostate cancer
Company intelligence / Profile preview
Hyundai ADM Bio provides comprehensive CRO services across Asia, including clinical development, pharmacovigilance, regulatory affairs, and quality assurance. The company has developed a novel oral formulation of docetaxel ("OTX-M") using a proprietary hybrid delivery platform that dramatically increases bioavailability without metabolic inhibitors. Preclinical results show strong anti-tumor efficacy with improved safety compared to traditional injectable chemotherapy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hyundai ADM Bio.